Network Pharmacology-based Research into the Mechanism of the Treatment of Mammary Hyperplasia and Perimenopausal Syndrome by Erxian Tang Based on"the Same Therapy for Different Diseases"
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
目的:基于网络药理学探讨二仙汤"异病同治"乳腺增生和围绝经期综合征的作用机制.方法:通过中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology da-tabase and analysis platform,TCMSP)筛选二仙汤中6味中药的活性成分并预测其潜在靶点;通过人类基因数据库(the human gene database,GeneCards)及在线人类孟德尔遗传数据库(online mendelian in-heritance in man,OMIM)平台检索乳腺增生和围绝经期综合征的疾病靶点,借助Venn在线工具构建药物与两种疾病的交集靶点.运用Cytoscape 3.7.2软件构建"药物-成分-靶点-疾病"网络;利用STRING数据库构建PPI网络,按Dgree值大于等于平均值进一步筛选核心靶点;采用DAVID数据库进行基因本体论(gene on-tology,GO)富集分析,同时实现京都基因与基因组百科全书(kyoto encyclopedia of genes and genomes,KEGG)通路富集分析.结果:根据口服生物利用度(oral bioavailability,OB)≥30%和药物类药性(drug-likeness,DL)≥0.18筛选得到二仙汤有效活性成分104个,预测潜在作用靶点147个;通过筛选得到乳腺增生靶点4153个,围绝经期综合征靶点155个,药物与疾病的交集靶点29个,其中IL-6、VEGFA、TNF、TP53、ESR1、CAT、IL-1β等可能是二仙汤治疗乳腺增生和围绝经期综合征的关键靶点.活性成分及靶点主要参与DNA模板转录正调控、基因表达的正调控、胞外间隙、胞外区、类固醇结合、酶结合等;靶基因主要富集在TNF、NOD样体、HIF-1、癌症、PI3K-Akt等信号通路.结论:二仙汤可能通过调控PI3K-Akt、HIF-1等信号通路达到防治乳腺增生和围绝经期综合征的目的.
Objective:To explore the mechanism of the treatment of mammary hyperplasia and perimenopausal syndrome by Erxian Tang based on"the same therapy for different diseases"using network pharmacology.Methods:To survey the mechanism of treating mammary hyperplasia and perimenopausal syndrome(PMS)by Erxian Tang based on network pharmacology and"the same therapy for different diseases".Methods:The effective active ingredients of six drugs in Erxian Tang were searched and screened via TCMSP,and its potential targets were predicted;disease targets of mammary hyperplasia and PMS were searched via GeneCards and OMIM,the intersection targets between drugs and two kinds of diseases were constructed via Venn online tool.The network of"drug-ingredients-targets-disease"was built using Cytoscape 3.7.2 software;PPI network was established utilizing STRING database,to further screen the core targets in light of degree values≥the average one;GO and KEGG pathway enrichment analysis were performed using DAVID database.Results:All 104 effective active ingredients were screened according to OB≥30%and DL≥0.18,and 147 potential targets were predicted;4153 targets of mammary hyperplasia and 155 targets related to PMS were gained,and 26 intersected targets of disease and drug,among which,IL-6,VEGFA,TNF,TP53,ESR1,CAT and IL-1β might be the key targets of Erxian Tang in the treatment of mammary hyperplasia and PMS.Active ingredients and targets mainly participated in positive regulation of DNA template transcription,positive regulation of gene expression,extracellular gap,extracellular region,steroid binding and enzyme binding;target genes were mainly enriched in TNF signaling pathway,NOD-like receptor signaling pathway,HIF-1 signaling pathway,cancer signaling pathway and PI3K-Akt signaling pathway.Conclusion:Erxian Tang could prevent and treat mammary hyperplasia and PMS possibly through regulating PI3K-Akt and HIF-1 signal pathways.
mammary hyperplasiaperimenopausal syndromethe same therapy for different diseasesnetwork pharmacologyErxian Tang
NETL
NSTL
万方数据
